胶质瘤
髓源性抑制细胞
医学
癌症
背景(考古学)
免疫系统
脑瘤
癌症研究
免疫疗法
恶性肿瘤
癌细胞
免疫学
免疫检查点
抑制器
内科学
生物
病理
古生物学
作者
Mohammad Salemizadeh Parizi,Fatemeh Salemizadehparizi,Saeed Abdolhosseini,Shohreh Vanaei,Ali Manzouri,Farnoosh Ebrahimzadeh
标识
DOI:10.1007/s10787-021-00878-9
摘要
The most fatal malignancy of the central nervous system (CNS) is glioblastoma. Brain cancer is a 'cold' tumor because of fewer immunoregulatory cells and more immunosuppressive cells. Due to the cold nature of brain cancers, conventional treatments which are used to manage glioma patients show little effectiveness. Glioma patients even showed resistance to immune checkpoint blockade (ICB) and no significant efficacy. It has been shown that myeloid-derived suppressor cells (MDSCs) account for approximately 30-50% of the tumor mass in glioma. This study aimed to review MDSC function in brain cancer, as well as possible treatments and related challenges. In brain cancer and glioma, several differences in the context of MDSCs have been reported, including disagreements about the MDSC subtype that has the most inhibitory function in the brain, or inhibitory function of regulatory B cells (Bregs). There are also serious challenges in treating glioma patients. In addition to the cold nature of glioma, there are reports of an increase in MDSCs following conventional chemotherapy treatments. As a result, targeting MDSCs in combination with other therapies, such as ICB, is essential, and recent studies with the combination therapy approach have shown promising therapeutic effects in brain cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI